CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Shaun Foy

Rodger Novak

Daniel Anderson

Emmanuelle Charpentier

CRISPR Therapeutics AG

Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

BridgeBio Pharma is a self-described biopharmaceutical company focused on developing and commercializing transformative medicines for serious diseases. It focuses on gene-based and genetic medicine.

BridgeBio Pharma

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Instil Bio, Inc.

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Bill & Melinda Gates Foundation

EcoR1 Capital

SR One

Wellington Capital Management

New Leaf Venture Partners

Franklin Templeton

Clough Capital Partners

New Enterprise Associates

Abingworth

Versant Ventures

Vertex Pharmaceuticals

CRISPR Therapeutics

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the conditional approval of the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for #SickleCellDisease and #BetaThalassemia. 

#Breaking: The U.S. FDA approves the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for #SickleCellDisease. Learn more: https://bit.ly/4apMw9p

Today, we provided an update on our immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T cell product candidates and we announced expansion into autoimmune disease. Learn more here: https://bit.ly/4a8zpsM

#Breaking: The UK Medicines and Healthcare products Regulatory Agency (MHRA) approves the treatment for #SickleCellDisease and #BetaThalassemia in Great Britain. This a historic scientific milestone arising out of our collaboration with Vertex. Learn more: crisprtx.com

Today was an exciting day as Dr. PK Morrow, CRISPR Therapeutics Chief Medical Officer, presented preclinical data on our investigational programs for the treatment of cardiovascular disease in two oral sessions at the American Heart Association Scientific Sessions. Learn more: https://bit.ly/47oCkLX #AHA23

Metric
Company Name	CRISPR Therapeutics AG	Biotech 365	BridgeBio Pharma	Instil Bio, Inc.
Symbol	CRSP			TIL
MSH ID	COM:CRISPRTX	COM:BIOTECH-365	COM:BRIDGEBIOPHARMA	COM:INSTILBIO
Market	STOCKS	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare	Financial Services & Finance	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology Business Services	Biotechnology	Biotechnology
Country	CH	FR	US	US
Stage			Post-IPO Equity
Employee Count	407			49
Website	crisprtx.com	biotech-365.com	bridgebiopharma.com	instilbio.com
LinkedIn	crispr-therapeutics
Founders

Metric
Market Cap	4.72B			65.10M
Enterprise Value
Monthly Web Traffic		68	23.81K	12.72K
Web Traffic Growth		-0.57	0.19	-0.76
Valuation
Raised Capital			250M

Metric
Revenue	370M
Revenue (LTM)
Revenue (NTM)
Gross Profit	239.75M
EBITDA	-202.70M
Operating Income	-222.54M
Net Income	-153.61M
EPS	-1.94
Diluted EPS	-1.94
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.65
Operating Profit Margin	-0.60
EBITDA Margin	-0.55
Net Profit Margin	-0.42
Return on Equity	-0.08
Return on Assets	-0.07
Return on Capital Employed	-0.10

COM:CRISPRTX

CRISPR Therapeutics AG

Last Close

46.29

22/11 21:00

Market Cap

4.72B

Beta: -

Volume Today

774

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-14.48
P/B Ratio	2.96
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	21.12
EV Multiple	-11.92

Metric
Days Sales Outstanding
Days Payables Outstanding	81.53
Days Inventory Outstanding
Operating Cycle	197.30
Cash Conversion Cycle	90.40
Asset Turnover	0.17

Metric
Operating Cash Flow	-260.38M
Free Cash Flow	-272.35M
Cash Flow to Debt	-0.11
Operating Cash Flow/Sales	-0.13
Free Cash Flow Yield	-0.06

Metric
Cash & Equivalents	389.48M
Accounts Receivable	-200M
Inventory
Goodwill
Debt to Capitalization	0.11
Debt to Assets	0.12
Current Ratio	15.83
Quick Ratio	17.81

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.50
R&D to Revenue	2.33
SG&A to Revenue	0.48